Urinary Tract, Sexual Organs, and Pregnancy Conditions  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
NCT00221286: Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

Terminated
3
2
Europe
pegylated interferon alfa-2a, tenofovir DF / emtricitabine combination therapy, pegIFN / TDF / FTC combination therapy
University Hospital, Bonn, Hoffmann-La Roche
Chronic Hepatitis B, HIV Infections
01/07
01/07
NCT00296972: Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication

Terminated
3
100
Canada
peg interferon plus ribavirin
University Health Network, Toronto, Hoffmann-La Roche
Chronic Hepatitis C, HIV Infections
 
04/07
NCT00122616: Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C

Completed
3
52
Europe
Peginterferon alpha-2a (Pegasys®), Ribavirin, HIV antiretroviral therapy
French National Agency for Research on AIDS and Viral Hepatitis, Hoffmann-La Roche
HIV Infections, Hepatitis C, Chronic
03/09
03/09
NCT01479868: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Checkmark
Sep 2014 - Sep 2014: 
Checkmark CROI 2014
Mar 2014 - Mar 2014: CROI 2014
Checkmark Primary results of naïve/relapser HIV/HCV co-infected patients at EACS
More
Completed
3
109
US, Canada, Europe
TMC435, Pegylated interferon alpha-2a, Ribavirin
Janssen R&D Ireland
Hepatitis C Virus Genotype-1
08/13
08/13
NCT01471574 / 2011-003067-30: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Completed
3
549
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Ribavirin, Copegus®, PEG-Interferon alfa 2a, Pegasys®, Pegylated interferon
Bristol-Myers Squibb
Hepatitis C, Genotype 1
06/14
09/14
NCT02829775 / 2004-002093-30: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Completed
2/3
9
Canada, Europe, RoW
Pegylated Interferon Alfa-2a, Pegasys, Recombinant Interferon Alfa 2a, Roferon-A
Hoffmann-La Roche
Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma
01/08
01/08
HB01EMVIPEG, NCT00391638: Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

Completed
2/3
56
Europe
TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a)
French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Roche Pharma AG
Hepatitis B, HIV Infections
05/11
10/12
No, NCT01006031 / 2009-009438-34: Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous nresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

Completed
2/3
25
Europe
Pegylated interferon alfa-2a and Ribavirin, Pegasys, Copegus
Sociedad Andaluza de Enfermedades Infecciosas
Liver Cirrhosis, Hepatitis C Virus, HIV Infection
12/11
12/11

Download Options